Retrospective Observation of Liver Function Tests in Biologic-Treated Patients with Psoriasis, Psoriatic Arthritis, and/or Hidradenitis Suppurativa
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s870
DOI: 10.25251/2qx7aa11 ↗Abstract
Introduction Although rare cases of elevated liver transaminases occur among patients with psoriasis (PSO), psoriatic arthritis (PsA), and/or hidradenitis suppurativa (HS) receiving biologic or oral targeted systemic treatments, liver function test (LFT) monitoring recommendations are inconsistent. This study aimed to understand real-world LFT monitoring practices among patients with PSO, PsA, and/or HS treated with biologic or oral targeted treatments. We assessed the frequency of LFT abnormalities (outside reference range) and elevations (>3× Upper Limit of Normal [ULN]) and whether these led to treatment modifications. Procedure A real-world retrospective cohort study of adult patients with PSO, PsA, and/or HS initiating a biologic or oral targeted systemic treatment from 01/2021–06/2023 was conducted at an academic medical center in the southeastern US (data source: electronic health record). LFTs were quantified at baseline (within 6 months of prescription) and 12 months post-initiation. LFT assessments at follow-up were analyzed using multivariable negative binomial regression. Results Among 393 patients (median age: 50.1 years; female: 62.3%), most had PSO (86.3%), then PsA (64.4%) and HS (10.9%); 59.8% had >1 diagnosis (typically PSO and PsA). Biologic or oral targeted systemic treatments initiated included tumor necrosis factor inhibitor (TNFi; 45.5%) and phosphodiesterase-4 inhibitor (PDE4i; 27.7%). Overall, 78.6% (309/393) of patients had baseline LFT monitoring; 48.2% (149/309) of patients had ≥1 abnormal (outside of reference range) LFTs, and 0.7% (2/309) of patients had ≥1 elevated LFTs (>3x upper limit of normal [ULN]). During follow-up, 67.7% (n=266) had LFTs (median LFTs [IQR]: 1.0 [1.0–2.0]); 51.9% (138/266) of patients had ≥1 abnormal LFTs, and 1.1% (3/266) of patients had ≥1 elevated LFTs. Additionally, 48.3% (100/207) of individual abnormal LFTs were resolved, with a median (IQR) time to resolution of 151.0 [89.0–204.0] days. Patients with concurrent treatments (incidence rate ratio [IRR]: 1.67; 95% confidence interval [CI]: 1.35–2.06) and patients with comorbidities (IRR: 1.25; 95% CI: 1.00–1.57) had more frequent LFT monitoring. Treatment modifications due to LFT elevations were rare (1/393 patients). Conclusion Most patients initiating a biologic or oral targeted systemic treatment had ≥1 LFTs in the first year of treatment, although LFT elevations and treatment modifications were rare.
EUVIMED